Alexion Pharmaceuticals Company Updates | Glassdoor

Company Updates

  • http://glassdoor.com/slink.htm?key=vQidg

    Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to extend the current therapeutic indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.

  • http://glassdoor.com/slink.htm?key=vQtHQ

    Alexion Names Paul Clancy Chief Financial Officer

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul J. Clancy, a seasoned financial executive with 30 years of experience, will join the company on July 10, 2017 and will assume the role of Chief Financial Officer (CFO) effective July 31, 2017.

  • http://glassdoor.com/slink.htm?key=vQEZc

    Alexion Announces Additions to Executive Leadership Team

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced key additions to its executive leadership team effective June 5, 2017. Reporting to Chief Executive Officer, Ludwig Hantson will be: John Orloff, M.D., Executive Vice President, Head of Research & Development, Anne-Marie Law, Executive Vice President, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer.

  • http://glassdoor.com/slink.htm?key=vQBWv

    Alexion Reports First Quarter 2017 Results | Alexion Pharmaceuticals, Inc

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2017. Total revenues in the quarter were $870 million, a 24 percent increase compared to the same period in 2016. First quarter revenues included a benefit of $29 million from a change in revenue recognition in 2017 for certain non-U.S.

  • http://glassdoor.com/slink.htm?key=vQdaw

    Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, effective immediately.

  • http://glassdoor.com/slink.htm?key=vQvrb

    Uncommon Strength | Uncommon Strength

    Living with or caring for someone with a rare disease requires strength. It takes a true hero.

  • http://glassdoor.com/slink.htm?key=vQvrs

    FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) to extend the indication for Soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

  • http://glassdoor.com/slink.htm?key=vQvu6

    Alexion Celebrates 25th Anniversary on Rare Disease Day 2017

    For 25 years, Alexion has fought alongside those who are rarely seen. With science and determination, we give hope to those with ultra-rare diseases.

  • http://glassdoor.com/slink.htm?key=vQnoS

    FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement, which is being evaluated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • http://glassdoor.com/slink.htm?key=vQnYj

    Newsroom: Press Releases and Media Materials | Alexion, Rare Disease Leader

    Newsroom, featuring press releases about Alexion, a global biopharmaceutical company and leader in developing and delivering life-transforming therapies for patients with devastating and rare diseases.

Work at Alexion Pharmaceuticals? Share Your Experiences

Alexion Pharmaceuticals
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or